CHITA – a registry of in vitro NAMs
If we want to replace animal testing in biomedical research, how do we find human-relevant alternatives? It’s not that simple. There are 1000s of human cell-based assays and systems that…
Faster adoption of alternatives to animals in biomedical research is a worthy goal for both scientific and ethical reasons. Addressing key elements of technology readiness for cell-based alternatives (in vitro…
The ToxCast program (Toxicity Forecaster) is a long running research program at the US EPA that has been steadily supporting alternatives to animals since 2007. The ToxCast program has generated…
Whether you call them “Novel Alternative Methods”, “New Approach Methods”, or non-animal methods, NAMs research is gaining support at NIH. Biomedical researchers working to promote human-relevant science will be happy…
Where are we with validation of assays to replace animals for product testing? The short answer: not very far. While many innovative platforms with potential as animal alternatives have been…
A recent paper from NTP showcases the application of mechanism-based NAMs for prediction of cardiotoxic potential. In a previous post, Getting Back on Track with NAMs at FDA, we encouraged…
Has FDA lost it’s way with NAMs? NAMs or New Alternative Methodologies is the term used by FDA for new regulatory tools to improve predictivity and help replace, reduce and/or…
A strong chain of translatability is crucial for successful drug discovery programs. The chain of translatability is a molecular-level association between the mechanisms that drive the assay phenotype, the preclinical disease…
Developing phenotypic assays that model human disease is a heavy lift. Our understanding of disease biology is limited. And there are so many variables, it’s hard to know where to…
